The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription.

Fielding, S L; Flower, M A; Ackery, D M; Kemshead, J; Lashford, L S; Lewis, I J

Fielding, S L; Flower, M A; Ackery, D M; Kemshead, J; Lashford, L S; Lewis, I J.

Afiliación

Fielding SL; Physics Department, Royal Marsden Hospital, Sutton, Surrey, UK.

Radiother Oncol ; 25(1): 73-6, 1992 Sep.

Article en En | MEDLINE | ID: mdl-1410594

RESUMEN

A UK multi-centre study has been carried out to collect medical and dosimetry data from treatments with 131I-metaiodobenzylguanidine (mIBG) for patients suffering from resistant neuroblastoma. All data have been acquired in a standardised way, following strict physics and clinical protocols. The accuracy of three different methods of dose prescription was studied. The results show that the most accurate method involved the use of an initial tracer study to determine the therapeutic activity required to deliver a predetermined absorbed whole-body (WB) dose.

Asunto(s)

Antineoplásicos/uso terapéutico; Radioisótopos de Yodo/uso terapéutico; Yodobencenos/uso terapéutico; Neuroblastoma/radioterapia; 3-Yodobencilguanidina; Niño; Humanos; Radiometría; Dosificación Radioterapéutica

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radioisótopos de Yodo / Yodobencenos / Neuroblastoma / Antineoplásicos Tipo de estudio: Clinical_trials / Guideline Límite: Child / Humans Idioma: En Revista: Radiother Oncol Año: 1992 Tipo del documento: Article Pais de publicación: Irlanda

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links